Where are we with adjuvant therapy of stage III and IV melanoma in 2009?

No abstract is available for this paper.

• Publication year

  2009

• Venue

  The Journal of the National Comprehensive Cancer Network

• Publication date

  2009-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.6004/JNCCN.2009.0022PMID 19401062
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684

  2023cited by this paper
• Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

  2009cited by this paper
• Overview of Molecular Pathways in Melanoma

  2008cited by this paper
• Phase II trial of neoadjuvant temozolomide in advanced melanoma

  2008cited by this paper
• Final results of the Sunbelt Melanoma Trial

  2008cited by this paper
• Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

  2008cited by this paper
• Efficacy of interferon alpha 2a in 18 versus 60 months of treatment in patients with primary melanoma of ≥ 1.5 mm tumor thickness: A randomized phase III DeCOG trial

  2008cited by this paper
• Impact of IFNα2b upon pSTAT3 and the MEK/ERK MAPK Pathway in Melanoma

  2008cited by this paper
• Detection of melanoma micrometastases in sentinel nodes - the cons.

  2008cited by this paper
• Practical guidelines for the management of interferon‐α‐2b side effects in patients receiving adjuvant treatment for melanoma

  2008cited by this paper
• The MAPK pathway in melanoma

  2008cited by this paper
• Adjuvant high‐dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor.

  2008cited by this paper
• Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis.

  2008cited by this paper
• Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Grou

  2008cited by this paper
• Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)

  2007cited by this paper
• Distinct Sets of Genetic Alterations in Melanoma

  2007cited by this paper
• Stage-IV Melanoma and Pulmonary Metastases: Factors Predictive of Survival

  2007cited by this paper
• Chemotherapy for metastatic melanoma

  2007cited by this paper
• An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites

  2007cited by this paper
• Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma

  2007cited by this paper
• Estimates of Stage-Specific Survival Are Altered by Changes in the 2002 American Joint Committee on Cancer Staging System for Melanoma

  2006cited by this paper
• Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.

  2006cited by this paper
• Somatic activation of KIT in distinct subtypes of melanoma.

  2006cited by this paper
• Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma

  2006cited by this paper
• Estimates of stage‐specific survival are altered by changes in the 2002 American Joint Committee on Cancer staging system for melanoma

  2006cited by this paper
• Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-CTLA-4

  2005cited by this paper
• Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

  2005cited by this paper
• Distinct sets of genetic alterations in melanoma.

  2005cited by this paper
• Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

  2005cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma

  2004cited by this paper
• Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035.

  2004cited by this paper
• Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.

  2004cited by this paper
• Pathologic analysis of sentinel lymph nodes in melanoma patients: Current and future trends

  2004cited by this paper
• Contemporary surgical treatment of advanced-stage melanoma.

  2004cited by this paper
• Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials.

  2003cited by this paper
• Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial.

  2002cited by this paper
• Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group.

  2002cited by this paper
• Treating cancer with PEG Intron

  2002cited by this paper
• Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

  2001cited by this paper
• Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial.

  2001cited by this paper
• High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.

  2001cited by this paper
• Patient preferences for adjuvant interferon alfa-2b treatment.

  2001cited by this paper
• Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor.

  2000cited by this paper
• High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

  2000cited by this paper
• Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

  1998cited by this paper
• Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.

  1998cited by this paper
• Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.

  1998cited by this paper
• Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases.

  1997cited by this paper
• Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

  1996cited by this paper
• Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma.

  1995cited by this paper
• Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine

  1992cited by this paper
• Sequential chemoimmunotherapy in the treatment of metastatic melanoma.

  1992cited by this paper
• An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients after surgical removal of a primary melanoma of the skin. A phase III adjuvant study. EORTC protocol 18761

  1988cited by this paper
• Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG

  1987cited by this paper
• A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.

  1982cited by this paper
• DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) surgical adjuvant study COG PROTOCOL 7040

  1981cited by this paper

• Survival of patients with stage IIIC and IIID melanomas with nodal metastases in the light of new therapies

  2022cites this paper
• Ternary Nanoparticles with a Sheddable Shell Efficiently Deliver MicroRNA-34a against CD44-Positive Melanoma.

  2017cites this paper
• Cutaneous and Temporal Bone Malignancies

  2014cites this paper
• CD 24 expression predicts poor prognosis for patients with cutaneous malignant melanoma

  2014cites this paper
• CD24 expression predicts poor prognosis for patients with cutaneous malignant melanoma.

  2014cites this paper
• Interferon alpha for the adjuvant treatment of cutaneous melanoma.

  2013cites this paper
• Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients

  2012cites this paper
• Targeting CD20 in melanoma patients at high risk of disease recurrence.

  2012cites this paper
• Targeting the RAS pathway in melanoma.

  2012cites this paper
• The Impact of Surgery on Survival of Patients With Cutaneous Melanoma: Revisiting the Role of Primary Tumor Excision Margins

  2011cites this paper
• Inflammatory signaling compromises cell responses to interferon alpha

  2011cites this paper
• Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects

  2011cites this paper
• Multivalent immunity targeting tumor-associated antigens by intra-lymph node DNA-prime, peptide-boost vaccination

  2011cites this paper
• A new era: melanoma genetics and therapeutics

  2011cites this paper
• Inactivation of isoprenylcysteine carboxyl methyltransferase reduces proliferation of BRAF and NRAS mutated human melanoma cells

  2011cites this paper
• An unusual presentation of metastatic melanoma

  2011cites this paper
• Genetic changes in melanoma progression

  2011cites this paper
• Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatment

  2010influential citation
• The anticancer face of interferon alpha (IFN-alpha): from biology to clinical results, with a focus on melanoma.

  2010cites this paper
• P31 NexrutineR: a novel agent for malignant melanoma

  2010cites this paper
• P32 Erlotinib in combination with different chemotherapeutics is active in a SCID mouse/human melanoma model

  2010cites this paper
• Molecular therapeutic approaches to melanoma.

  2010cites this paper
• P29 New heteroaromatic compounds for a targeted melanoma therapy: factors modulating subcellular distribution

  2010cites this paper
• Sentinel lymph node biopsy in melanoma management: its significance and potential problems

  2009cites this paper